Interestingly reduced protein N-Glycosylation has already been shown to be a therapeutic vulnerability in solid cancers22 and leukaemia53 and specifically in FLT3ITD AML due to reduced surface FLT3 expression upon glycosylation inhibition54. The gene discussed is FLT3; the disease is acute myeloid leukemia.